Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × COVID-19 × sotrovimab × Clear all

Phase

Phase 2/3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Vasculitis 1 Neoplasms 1 Lupus Erythematosus, Systemic 1 Glomerulonephritis 1 COVID-19 1

Interventions

sotrovimab 1 remdesivir 1 ciclesonide 1 Standard of Care 1 Niclosamide 1 COVID-19 Serotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04870333 2025-06-20

PROTECT-V

Cambridge University Hospitals NHS Foundation Trust

Phase 2/3 Completed

COVID-19, Glomerulonephritis, Lupus Erythematosus, Systemic, Neoplasms, Vasculitis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡